I did some quick math - GNBT - $32 million mark
Post# of 36536
GNBT - $32 million market cap
NVAX - $13 billion market cap
MRNA - $65.51 billion market cap
If GNBT's market cap = $13 billion - then GNBT's PPS = $112, or 400x current PPS
If GNBT's market cap = $65.51 billion - then GNBT's PPS = $565 or 2018x current PPS
That's what we can look forward to when GNBT's vaccine become commercially available...this does not even include other potentials e.g. MSO/HMO (per cc, Dr. Patel is involved), RPM, Excellagen, Regentry, Altucell, AE37 (breast cancer and prostate cancer trials which Rich Purcell said Merck has expresses interest)
Let's hope GNBT/NGIO will get funding or partnership with big pharma after their phase 1 data as discussed in the cc.